@article{ad7735b1678940009e781877a6c91d53,
title = "Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile",
abstract = "In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab({\textregistered})) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.",
keywords = "Alemtuzumab, Biology, CLL, Chronic lymphocytic leukemia, Fludarabine, Young, Alemtuzumab, Biology, CLL, Chronic lymphocytic leukemia, Fludarabine, Young",
author = "Luca Laurenti and Mauro, {Francesca R.} and Stefano Molica and Agostino Cortelezzi and Carella, {Angelo M.} and Francesco Zaja and Annalisa Chiarenza and Francesco Angrilli and Francesco Nobile and Roberto Marasca and Caterina Musolino and Maura Brugiatelli and Alfonso Piciocchi and Marco Vignetti and Paola Fazi and Giuseppe Gentile and {De Propris}, {Maria S.} and Starza, {Irene Della} and Marilisa Marinelli and Sabina Chiaretti and {Del Giudice}, Ilaria and Mauro Nanni and Francesco Albano and Antonio Cuneo and Anna Guarini and Robin Fo{\`a}",
year = "2014",
doi = "10.1016/j.leukres.2013.11.009",
language = "English",
volume = "38",
pages = "198--203",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Oxford,United Kingdom: Elsevier Science Limited -Oxford : Pergamon, 1977-",
}